Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age35-65
SponsorBiocells Medical
About this trial
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.
Eligibility criteria
Qualifiers
Multiple System Atrophy (MSA-P or MSA-C)
Age range of 35 to 65 years
Disqualifiers
Other major neurological disorders
Severe cardiac/renal/hepatic impairment
Prior stem cell therapy
Trial design
Treatments tested in this trial
- MSCs
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov